News
Geron (GERN) Q1 2024 Earnings Call Transcript
Why Zoetis Stock Popped by Almost 6% on Thursday
Investors were meowing for animal healthcare specialist Zoetis (NYSE: ZTS) on Thursday, following the company's release of its latest quarterly results. These obviously pleased market participants
Cigna Group (CI) Q1 2024 Earnings Call Transcript
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several
Up More Than 70%, Is Nvidia Stock a Buy Right Now?
Many investors consider Nvidia (NASDAQ: NVDA) the ultimate artificial intelligence (AI) stock for two solid reasons: The company dominates the AI chip market and has turned this leadership into
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its stock in serious bargain territory. Speaking
1 Wall Street Analyst Thinks AT&T Stock Is Going to $20. Is It a Buy?
AT&T (NYSE: T) stock has struggled in recent years, but Barclays analyst Kannan Venkateshwar believes the company deserves a higher valuation, considering the recent subscriber gains for its
AEVIS VICTORIA SA – Revenues from operating divisions are increasing, with positive forecasts for the current year. Growth for 1Q2024 is 7.2%.
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
Sarepta Therapeutics (NASDAQ: SRPT)Q1 2024 Earnings CallMay 01, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Pfizer (PFE) Q1 2024 Earnings Call Transcript
Why Pfizer Stock Blasted More Than 6% Higher Today
Pfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
1 Top Growth Stock to Buy and Hold for 10 Years
A lot will change in the next 10 years, but our need for innovative medicines is unlikely to be one of them. That's one thing that makes some biotech companies exciting long-term investment
Padraig McDonnell Assumes Agilent CEO Role
Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
5 Top Stocks to Buy in May
Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names.
However, long-term investors know that the best way to view a quarterly
1 Magnificent Dividend Growth Stock That's Down 40% and Trading at a Once-in-a-Decade Valuation
So far, 2024 has been a year to forget for animal healthcare juggernaut Zoetis (NYSE: ZTS). Hit by the triple whammy of weak earnings, a formal investigation from the European Commission, and
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
I owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar over 60% in roughly two years was fun. Seeing Pfizer's share price fall nearly 60% from its peak
EQS-News: Bayer and Evotec collaborate to advance precision cardiology
EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
The market isn't rational always and everywhere. Sometimes, shares of excellent companies with bright futures almost inexplicably fail to keep pace with broader equities. When that happens, it's